• COVID-19
  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics

by Fred Pennic 07/10/2020 Leave a Comment

Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics

What You Should Know:

– Repurpose.AI, has partnered with Scripps Research to discover drug candidates that may be repurposed to treat COVID-19. 

– The partnership will leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover drug candidates to treat COVID-19. 


Scripps Research is teaming up with Repurpose.AI, an AI drug discovery company to develop COVID-19 therapeutics. The partnership will leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover drug candidates to treat COVID-19. Previously, the company has successfully utilized the platform to discover REP-001, REP-002, and REP-003 – three Phase II/III ready small molecule assets for the treatment of gastric, neurological, and weight disorders, respectively.

Partnership Details

Scripps Research scientists together with Calibr, its drug development division, will leverage its COVID-19 screening models and commitment to drug repurposing as part of the partnership. Calibr previously established the ReFRAME collection, the world’s leading collection of known drugs, comprising over 14,000 compounds that have been approved by the FDA for other diseases or have been extensively tested for human safety, which it is bringing to bear on the current pandemic. The collaborative work with Repurpose.AI will augment this effort by characterizing compounds not identified to date using conventional repurposed drug screening approaches.

 “We could not be more excited about our partnership with Scripps Research and Calibr. Like Repurpose.AI, Calibr is committed to ending the scourge of the global COVID-19 pandemic. Our goal is to move therapeutics from the computer to the clinic in a fraction of the time typically required to discover and bring new drugs to market and alleviate the suffering of patients afflicted by COVID-19. Creating therapeutics to treat COVID-19 also allows the global community to go back to work and for children to go back to school. Repurpose.AI and Calibr are committed to doing our part to ensure that happens sooner rather than later,” said Dr. Daniel Haders II, Ph.D., Executive Chairman at Repurpose.AI.

AI-Driven Drug Discovery

Repurpose.AI, a Nex Cubed digital health portfolio company, has harnessed the predictive prowess of artificial intelligence and machine learning with its ActivPred AI Drug Discovery Platform to discover drugs that may be repurposed to serve as therapeutics to treat patients suffering from COVID-19. The drugs that Repurpose.AI discovers for COVID-19 can enter clinical trials in as little as several months.

Repurpose.AI’s Drug Library

Repurpose.AI’s Drug Library is comprised of approximately 4,000 drug compounds that have been approved for commercial use by the U.S. FDA, or similar agencies, and 20,000+ drug compounds that are known to have successfully navigated a Phase I (human safety) clinical trial. All drugs have a full pre-clinical program, an existing or legacy supply chain, and are known to be safe and well-tolerated in humans.

RELATED:   Transitioning from Traditional to E-Fax: How Healthcare Communications are Transforming Post-COVID

Tagged With: AI, Artificial Intelligence, Clinical Trial, Clinical Trials, Coronavirus (COVID-19), digital health, Digital Therapeutics, Drug Discovery, FDA, Machine Learning, Scripps

[ultimatesocial networks="facebook,twitter,google,linkedin,mail" url="" custom_class="us-posts-bottom" align="left" count="false"]

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

« New Lighthouse Initiative to Provide De-identified Patient Data for VIRUS COVID-19 Registry
COVID-19 Has Permanently Shifted Patient Behavior Towards Virtual Care »

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Recent Articles

  • Cerner Leadership Changes, Other Key Executives Hires

    ... more
  • QGenda acquires Shift Admin – M&A

    QGenda Acquires Automated Provider Scheduling Platform Shift Admin – M&A

    ... more
  • Telehealth After COVID-19: What's Next for the Healthcare Industry?

    Transitioning from Traditional to E-Fax: How Healthcare Communications are Transforming Post-COVID

    ... more
  • FCC COVID-19 Telehealth Program Providers

    FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program

    ... more

Most Read

  • CVS Health Launches Senior Medical Alert System, Symphony CVS Health Launches Senior Medical Alert System, Symphony
  • 30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021 30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021
  • 20 COVID-19 Predictions and Trends for 2021 - Executive Roundup 20 COVID-19 Predictions and Trends for 2021 – Executive Roundup
  • 20 COVID-19 Predictions and Trends for 2021 - Executive Roundup MEDITECH Launches Quick Vaccination Solution to Streamline COVID-19 Vaccination Process
  • ONC Issues First Health IT Standards Bulletin Discussing USCDI & SVAP ONC Issues First Health IT Standards Bulletin Discussing USCDI & SVAP
  • 16 COVID-19 Predictions and Trends for 2021 Executive Roundup 12-Available-COVID-19-Vaccine-Management-Solutions-to-Know-In-Depth-1 17 Recently Launched COVID-19 Vaccine Management Solutions to Know
  • FDA Approves COVID-19 Oral Fluid Test for Use Nationwide In-Depth: 32 FDA-Approved COVID-19 Testing Kits
  • COVID-19 Deferrals Lead to 3 Major Conditions Payers/Providers Must Address in 2021 COVID-19 Deferrals Lead to 3 Major Conditions Payers/Providers Must Address in 2021
  • 5G in Healthcare: 7 Advantages & Disadvantages for Providers to Know 5G in Healthcare: 7 Advantages & Disadvantages for Providers to Know
  • FCC COVID-19 Telehealth Program Providers FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2020 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2021. HIT Consultant Media. All Rights Reserved. Privacy Policy |